XML 16 R24.htm IDEA: XBRL DOCUMENT v2.4.0.6
Operating Segments (Tables)
 3 Months Ended 12 Months Ended
Mar. 31, 2013
Dec. 31, 2012
Operating Segments [Abstract]    
Summary of segmental information
   
Three Months Ended
March 31,
 
   
2013
  
2012
 
Grant Revenue
      
Vaccines/BioDefense
 $829,849  $597,605 
BioTherapeutics
  70,505   49,813 
  Total
 $900,354  $647,418 
          
Loss from Operations
        
Vaccines/BioDefense
 $(30,995) $(128,366)
BioTherapeutics
  (457,625)  (726,042 ) 
Corporate
  (599,277 )  (586,582 ) 
  Total
 $(1,087,897) $(1,440,990)
         
Amortization and Depreciation Expense
        
Vaccines/BioDefense
 $27,667  $27,997 
BioTherapeutics
  28,395   28,840 
Corporate
  436   507 
  Total
 $56,498  $57,344 
          
Interest Income
        
Corporate 
 $483  $2,235 
          
Stock-Based Compensation
        
Vaccines/BioDefense
 $11,121  $2,130 
BioTherapeutics 
  21,036   56,240 
Corporate
  47,335   59,064 
   Total
 $79,492  $117,614 
 
   
As of
March 31,
 2013
  
As of
December 31,
2012
 
        
Identifiable Assets
      
Vaccines/BioDefense
 $936,695  $628,494 
BioTherapeutics
  519,391   566,111 
Corporate
  2,795,789   3,510,499 
  Total
 $4,251,875  $4,705,104 
 
   
For the Year Ended December 31,
 
   
2012
  
2011
 
Revenues
      
Vaccines/BioDefense
 $2,919,677  $2,010,234 
BioTherapeutics 1
  224,943   5,652,588 
                       Total
 $3,144,620  $7,662,822 
          
Loss from Operations
        
Vaccines/BioDefense
 $(33,636) $(154,395)
BioTherapeutics
  (2,203,721 )  (1,278,156 )
Corporate
  (2,453,311 )  (1,527,644 )
                       Total
 $(4,690,668) $(2,960,195)
          
Amortization and Depreciation Expense
        
Vaccines/BioDefense
 $38,589  $42,640 
BioTherapeutics
  190,003   181,213 
Corporate
  2,038   2,174 
                       Total
 $230,630  $226,027 
          
Interest Income 
        
Corporate 
 $6,202  $7,444 
          
Stock-Based Compensation
        
Vaccines/BioDefense
 $44,484  $78,622 
BioTherapeutics 
  84,020   426,666 
Corporate 
  333,666   210,517 
                       Total 
 $462,170  $715,805 
    
   
As of December 31,
 
    2012   2011 
Identifiable Assets
        
Vaccines/BioDefense
 $628,494  $689,266 
BioTherapeutics
  566,111   753,767 
Corporate
  3,510,499   6,780,625 
                       Total
 $4,705,104  $8,223,658 
 
1
BioTherapeutics revenues for 2011 includes the receipt of a $5 million licensing fee from Sigma-Tau in July 2011.